Dr. Steven D. Averbuch will bring more than three decades of oncology drug experience to Caris Life Sciences’ Scientific Advisory Board after retiring as Vice President and Head of Precision Medicine at Bristol-Myers Squibb.
The board is a group of cancer researchers, bioinformaticians and clinical oncologists who help guide and accelerate the work Caris does in improving precision cancer care.
Averbuch has been a part of several drug and companion diagnostic approvals in major markets, and recently retired from BMS where he led integrated biomarker and pharmacodiagnostic work in research and development. Averbuch also had leadership roles at Merck Research Laboratories, and appointments at Mount Sinai School of Medicine in New York and the U.S. Public Health Service School of Medicine. He sits on boards and committees for the Personalized Medicine Coalition, the National Biomarker Development Alliance, and the University of Kansas Institute for Advancing Medical Innovation.
“We are thrilled to welcome Dr. Averbuch, a champion for precision cancer care, to our Scientific Advisory Board,” said George Poste, Scientific Advisory Board Chairman via release. “His expertise in oncology clinical trial design and experience in immuno-oncology bolsters Caris’ efforts to advance precision medicine and improve clinical outcomes.”
“I am delighted to join Caris’ Scientific Advisory Board and support their pursuit in developing industry-leading offerings that enhance personalized cancer treatments,” said Averbuch via release. “The opportunity to collaborate with this exceptional class of scientific and clinical minds is an extraordinary privilege.”
